ERBB2 and breast carcinoma: Adjuvant treatment with anti-human epidermal growth factor receptor 2 (HER2) therapy (such as trastuzumab and other biosimilars) for a total duration of 12 months is the current standard of care for most patients with HER2-positive early breast cancer (EBC) [1,2,3].